Jin Medical International Ltd. ZJYL
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS0.01
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $20.7M | $23.5M | $19.8M | $19.2M | $20.8M | — |
| Cost of revenue | $14.6M | $14.0M | $13.0M | $13.0M | $14.4M | — |
| Gross profit | $6.0M | $9.5M | $6.8M | $6.2M | $6.4M | — |
| R&D | $1.6M | $1.5M | $1.5M | $1.9M | $1.6M | — |
| SG&A | $2.5M | $3.3M | $1.9M | $1.8M | $1.7M | — |
| Total operating expenses | $5.4M | $5.9M | $3.9M | $4.1M | $3.7M | — |
| Operating income | $608.2K | $3.6M | $2.9M | $2.1M | $2.6M | — |
| Interest expense | — | — | $182.7K | $181.6K | $9.5K | — |
| Pre-tax income | $1.6M | $4.2M | $3.2M | $2.7M | $2.9M | — |
| Income tax | $214.6K | $763.9K | $343.7K | $36.1K | $248.6K | — |
| Net income | $1.2M | $3.7M | $2.9M | $2.7M | $2.6M | — |
| EPS, basic | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | — |
| EPS, diluted | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | — |
| Shares, diluted (wtd. avg.) | $156.5M | $156.5M | $145.1M | $135.0M | $135.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $7.5M | $8.1M | $6.9M | $4.8M | $3.7M | $1.7M |
| Short-term investments | $22.2M | $18.6M | $9.8M | $2.3M | — | — |
| Receivables | $5.8M | $5.9M | $3.3M | $3.8M | — | — |
| Inventory | $4.9M | $5.2M | $5.1M | $6.7M | — | — |
| Total current assets | $44.1M | $42.8M | $31.1M | $18.9M | — | — |
| Property, plant and equipment | $7.9M | $1.5M | $1.5M | $1.6M | — | — |
| Other intangibles | $1.1M | $1.1M | $154.4K | — | — | — |
| Total assets | $53.4M | $45.8M | $32.9M | $20.9M | — | — |
| Accounts payable | $3.3M | $3.0M | $3.4M | $4.1M | — | — |
| Short-term debt | $18.8M | $11.3M | $4.1M | — | — | — |
| Total current liabilities | $23.8M | $17.2M | $8.9M | $5.7M | — | — |
| Total liabilities | $23.8M | $17.2M | $8.9M | $5.7M | — | — |
| Retained earnings | $20.9M | $20.0M | $16.9M | $14.4M | — | — |
| Total equity | $29.6M | $28.8M | $24.0M | $15.2M | $14.0M | $10.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $2.9M | -$1.2M | $3.1M | $1.6M | $5.8M | — |
| Depreciation and amortisation | $243.4K | $237.8K | $225.9K | $362.6K | $346.6K | — |
| Capital expenditure | $6.6M | $144.9K | $113.9K | $40.2K | $42.9K | — |
| Investing cash flow | -$10.8M | -$9.5M | -$7.7M | -$120.9K | -$1.1M | — |
| Financing cash flow | $7.4M | $11.7M | $6.9M | $121.9K | -$2.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-013870.
Others in SIC 3842
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $129.55B | 46.6x | 20.5% |
| EW | Edwards Lifesciences Corp | $51.82B | 49.1x | 11.5% |
| STE | STERIS plc | $21.90B | 28.3x | 8.7% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | $18.71B | 27.6x | 7.2% |
| ALGN | ALIGN TECHNOLOGY INC | $11.27B | 28.1x | 0.9% |
| MSA | MSA Safety Inc | $7.28B | 26.6x | 3.7% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $2.21B | — | 27.1% |
| CDRE | Cadre Holdings, Inc. | $1.27B | 29.2x | 7.5% |